Immunoadsorption: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(→Learn more: Add Sort article) |
Notjusttired (talk | contribs) m (fix duplicate template calls) |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Immunoadsorption''' is the technique by which pathogenic substances, especially undesirable antibodies, are removed from blood plasma. | '''Immunoadsorption''' is the technique by which pathogenic substances, especially undesirable antibodies, are removed from blood [[plasma]]. Immunoadsorption is considered to have fewer adverse effects than the use of therapeutic plasma exchange.<ref name="Pham, 2013">{{Cite book| last1 = Pham | first1 = H. P. | authorlink1 = | last2 = Schwartz | first2 = J. | authorlink2 = | title = Transfusion medicine and hemostasis: clinical and laboratory aspects.| date = 2013 | pmid = | doi = 10.1016/B978-0-12-397164-7.00079-3|url=|pages=525–527|chapter=79 - Immunoadsorption|edition=2|isbn=|location=Newnes|editor-last=Shaz|editor-first=B. H.|editor2-last=Hillyer|editor2-first=C.D.}}</ref> Several medical conditions, such as [[multiple sclerosis]]<ref name="Koziolek2018">{{Cite journal|last=Koziolek|first=Michael J.|last2=Tampe|first2=Desiree|last3=Bähr|first3=Matthias|last4=Dihazi|first4=Hassan|last5=Jung|first5=Klaus|last6=Fitzner|first6=Dirk|last7=Klingel|first7=Reinhard|last8=Müller|first8=Gerhard A.|last9=Kitze|first9=Bernd|date=2012-04-26|title=Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis|url=https://doi.org/10.1186/1742-2094-9-80|journal=Journal of Neuroinflammation|volume=9|issue=1|pages=80|doi=10.1186/1742-2094-9-80|issn=1742-2094|pmc=PMC3418188|pmid=22537481}}</ref> and chronic inflammatory demyelinating polyneuropathy (CIDP)<ref name="Lehmann2013">{{Cite book|last=Lehmann|first=Helmar C.|author-link=|last2=Hughes|first2=Richard A. C.|author-link2=|last3=Hartung|first3=Hans-Peter|author-link3=|date=2013-01-01|editor-last=Said|editor-first=Gérard|editor2-last=Krarup|editor2-first=Christian|title=Handbook of Clinical Neurology.|url=https://www.sciencedirect.com/science/article/pii/B9780444529022000230|chapter=23 - Treatment of chronic inflammatory demyelinating polyradiculoneuropathy|work=Peripheral Nerve Disorders|language=en|publisher=Elsevier|volume=115|series=3|pages=415–427|doi=10.1016/b978-0-444-52902-2.00023-0|pmc=|pmid=|quote=|via=}}</ref> may use immunoadsorption as part of their medical regimen. | ||
== | ==Theory== | ||
*2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME<ref>Scheibenbogen | A number of studies have found that a subset of [[ME/CFS]] patients have abnormal autoantibodies in their blood; immunoadsorption could be used to remove these autoantibodies with the aim of improving symptoms or potentially curing [[ME/CFS]] in those patients.<ref name="Scheibenbogen2018" /> | ||
==Evidence== | |||
*2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME<ref name="Scheibenbogen2018">{{Cite journal|last=Scheibenbogen|first=Carmen|author-link=Carmen Scheibenbogen|last2=Loebel|first2=Madlen|author-link2=Madlen Löbel|last3=Freitag|first3=Helma|author-link3=Helma Freitag|last4=Krueger|first4=Anne|author-link4=|last5=Bauer|first5=Sandra|author-link5=Sandra Bauer|last6=Antelmann|first6=Michaela|author-link6=|last7=Doehner|first7=Wolfram|last8=Scherbakov|first8=Nadja|last9=Heidecke|first9=Harald|date=2018-03-15|title=Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME|url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672|journal=PLOS ONE|language=en|volume=13|issue=3|pages=e0193672|doi=10.1371/journal.pone.0193672|issn=1932-6203|pmc=PMC5854315|pmid=29543914|access-date=|quote=|via=}}</ref> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672 (Full Text)] | |||
==Clinicians== | |||
==Risks and safety== | |||
==Costs and availability== | |||
==Learn more== | ==Learn more== | ||
| Line 10: | Line 18: | ||
==See also== | ==See also== | ||
*[[Autoimmune hypothesis]] | |||
*[[Autoantibody]] | |||
*[[Carmen Scheibenbogen]] | *[[Carmen Scheibenbogen]] | ||
==References== | ==References== | ||
{{Reflist}} | |||
{{ | |||
}} | |||
[[Category:Potential treatments]] | [[Category:Potential treatments]] | ||
Revision as of 18:31, September 28, 2021
Immunoadsorption is the technique by which pathogenic substances, especially undesirable antibodies, are removed from blood plasma. Immunoadsorption is considered to have fewer adverse effects than the use of therapeutic plasma exchange.[1] Several medical conditions, such as multiple sclerosis[2] and chronic inflammatory demyelinating polyneuropathy (CIDP)[3] may use immunoadsorption as part of their medical regimen.
Theory[edit | edit source]
A number of studies have found that a subset of ME/CFS patients have abnormal autoantibodies in their blood; immunoadsorption could be used to remove these autoantibodies with the aim of improving symptoms or potentially curing ME/CFS in those patients.[4]
Evidence[edit | edit source]
- 2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME[4] (Full Text)
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Learn more[edit | edit source]
- Wikipedia page for Immunoadsorption
- 2018, Hope for an ME/CFS Autoimmune Subset: A German Researcher Steps Forward (Carmen Scheibenbogen)
See also[edit | edit source]
References[edit | edit source]
- ↑ Pham, H. P.; Schwartz, J. (2013). "79 - Immunoadsorption". In Shaz, B. H.; Hillyer, C.D. (eds.). Transfusion medicine and hemostasis: clinical and laboratory aspects (2 ed.). Newnes. pp. 525–527. doi:10.1016/B978-0-12-397164-7.00079-3.
- ↑ Koziolek, Michael J.; Tampe, Desiree; Bähr, Matthias; Dihazi, Hassan; Jung, Klaus; Fitzner, Dirk; Klingel, Reinhard; Müller, Gerhard A.; Kitze, Bernd (April 26, 2012). "Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis". Journal of Neuroinflammation. 9 (1): 80. doi:10.1186/1742-2094-9-80. ISSN 1742-2094. PMC 3418188. PMID 22537481.
- ↑ Lehmann, Helmar C.; Hughes, Richard A. C.; Hartung, Hans-Peter (January 1, 2013). "23 - Treatment of chronic inflammatory demyelinating polyradiculoneuropathy". In Said, Gérard; Krarup, Christian (eds.). Handbook of Clinical Neurology. Peripheral Nerve Disorders. 3. 115. Elsevier. pp. 415–427. doi:10.1016/b978-0-444-52902-2.00023-0.
- ↑ 4.0 4.1 Scheibenbogen, Carmen; Loebel, Madlen; Freitag, Helma; Krueger, Anne; Bauer, Sandra; Antelmann, Michaela; Doehner, Wolfram; Scherbakov, Nadja; Heidecke, Harald (March 15, 2018). "Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME". PLOS ONE. 13 (3): e0193672. doi:10.1371/journal.pone.0193672. ISSN 1932-6203. PMC 5854315. PMID 29543914.
